File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00213-018-5081-7
- Scopus: eid_2-s2.0-85055736869
- PMID: 30357437
- WOS: WOS:000451058700017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effects of ketamine on brain function during response inhibition
Title | Effects of ketamine on brain function during response inhibition |
---|---|
Authors | |
Keywords | Antisaccades Experimental model system Eye movements Inhibitory control Ketamine Psychosis Schizophrenia |
Issue Date | 2018 |
Citation | Psychopharmacology, 2018, v. 235, n. 12, p. 3559-3571 How to Cite? |
Abstract | Introduction: The uncompetitive N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonist ketamine has been proposed to model symptoms of psychosis. Inhibitory deficits in the schizophrenia spectrum have been reliably reported using the antisaccade task. Interestingly, although similar antisaccade deficits have been reported following ketamine in non-human primates, ketamine-induced deficits have not been observed in healthy human volunteers. Methods: To investigate the effects of ketamine on brain function during an antisaccade task, we conducted a double-blind, placebo-controlled, within-subjects study on n = 15 healthy males. We measured the blood oxygen level dependent (BOLD) response and eye movements during a mixed antisaccade/prosaccade task while participants received a subanesthetic dose of intravenous ketamine (target plasma level 100 ng/ml) on one occasion and placebo on the other occasion. Results: While ketamine significantly increased self-ratings of psychosis-like experiences, it did not induce antisaccade or prosaccade performance deficits. At the level of BOLD, we observed an interaction between treatment and task condition in somatosensory cortex, suggesting recruitment of additional neural resources in the antisaccade condition under NMDAR blockage. Discussion: Given the robust evidence of antisaccade deficits in schizophrenia spectrum populations, the current findings suggest that ketamine may not mimic all features of psychosis at the dose used in this study. Our findings underline the importance of a more detailed research to further understand and define effects of NMDAR hypofunction on human brain function and behavior, with a view to applying ketamine administration as a model system of psychosis. Future studies with varying doses will be of importance in this context. |
Persistent Identifier | http://hdl.handle.net/10722/330585 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.053 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Steffens, M. | - |
dc.contributor.author | Neumann, C. | - |
dc.contributor.author | Kasparbauer, A. M. | - |
dc.contributor.author | Becker, B. | - |
dc.contributor.author | Weber, B. | - |
dc.contributor.author | Mehta, M. A. | - |
dc.contributor.author | Hurlemann, R. | - |
dc.contributor.author | Ettinger, U. | - |
dc.date.accessioned | 2023-09-05T12:12:01Z | - |
dc.date.available | 2023-09-05T12:12:01Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Psychopharmacology, 2018, v. 235, n. 12, p. 3559-3571 | - |
dc.identifier.issn | 0033-3158 | - |
dc.identifier.uri | http://hdl.handle.net/10722/330585 | - |
dc.description.abstract | Introduction: The uncompetitive N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonist ketamine has been proposed to model symptoms of psychosis. Inhibitory deficits in the schizophrenia spectrum have been reliably reported using the antisaccade task. Interestingly, although similar antisaccade deficits have been reported following ketamine in non-human primates, ketamine-induced deficits have not been observed in healthy human volunteers. Methods: To investigate the effects of ketamine on brain function during an antisaccade task, we conducted a double-blind, placebo-controlled, within-subjects study on n = 15 healthy males. We measured the blood oxygen level dependent (BOLD) response and eye movements during a mixed antisaccade/prosaccade task while participants received a subanesthetic dose of intravenous ketamine (target plasma level 100 ng/ml) on one occasion and placebo on the other occasion. Results: While ketamine significantly increased self-ratings of psychosis-like experiences, it did not induce antisaccade or prosaccade performance deficits. At the level of BOLD, we observed an interaction between treatment and task condition in somatosensory cortex, suggesting recruitment of additional neural resources in the antisaccade condition under NMDAR blockage. Discussion: Given the robust evidence of antisaccade deficits in schizophrenia spectrum populations, the current findings suggest that ketamine may not mimic all features of psychosis at the dose used in this study. Our findings underline the importance of a more detailed research to further understand and define effects of NMDAR hypofunction on human brain function and behavior, with a view to applying ketamine administration as a model system of psychosis. Future studies with varying doses will be of importance in this context. | - |
dc.language | eng | - |
dc.relation.ispartof | Psychopharmacology | - |
dc.subject | Antisaccades | - |
dc.subject | Experimental model system | - |
dc.subject | Eye movements | - |
dc.subject | Inhibitory control | - |
dc.subject | Ketamine | - |
dc.subject | Psychosis | - |
dc.subject | Schizophrenia | - |
dc.title | Effects of ketamine on brain function during response inhibition | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s00213-018-5081-7 | - |
dc.identifier.pmid | 30357437 | - |
dc.identifier.scopus | eid_2-s2.0-85055736869 | - |
dc.identifier.volume | 235 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 3559 | - |
dc.identifier.epage | 3571 | - |
dc.identifier.eissn | 1432-2072 | - |
dc.identifier.isi | WOS:000451058700017 | - |